Disease/Infection News

RSS

Study: PrEP treatment offers protection against HIV transmission in humanized mice

Systemic pre-exposure administration of antiretroviral drugs provides protection against intravenous and rectal transmission of HIV in mice with human immune systems, according to a new study published January 21, 2010 in the online journal PLoS ONE.

21 Jan 2010

Discovery of new class of compounds may help fight hepatitis C

Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.

21 Jan 2010

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.

21 Jan 2010

Study identifies new mechanism that causes allergic response in people

WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

Acyclovir does not reduce risk of HIV transmission for people infected with both HIV and HSV-2

A five-year international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment taken twice daily to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.

21 Jan 2010

Research shows strong links between COPD and heart function

A common lung condition, COPD (chronic obstructive pulmonary disease) diminishes the heart's ability to pump effectively even when the disease has no or mild symptoms, according to research published in the Jan. 21 issue of the New England Journal of Medicine.

21 Jan 2010

GSK to offer scientists access to compounds, lab space to fight malaria

Drugmaker GlaxoSmithKline (GSK)'s Chief Executive Officer Andrew Witty on Tuesday unveiled the company's plans to allow "free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries," Bloomberg reports (Randall, 1/20).

21 Jan 2010

One-legged cycling can improve overall fitness in COPD patients

People with chronic-obstructive pulmonary disease (COPD) often find themselves in a downward spiral when it comes to their health. COPD, which includes chronic bronchitis and emphysema, means that the elasticity of the lungs is destroyed.

21 Jan 2010

Circumcising newborn males cost effective strategy for HIV prevention, Rwandan study finds

Performing circumcisions on newborn boys to lower their risk for HIV infection later in life is more cost-effective than adolescent or adult circumcision, according to researchers at Rwanda's health ministry, Reuters reports.

21 Jan 2010

Researchers develop more effective way to predict the spread of foot-and-mouth disease

Combining technology and animal health, a group of Kansas State University researchers is developing a more effective way to predict the spread of foot-and-mouth disease and the impact of preventative measures.

20 Jan 2010

Data may help identify severity of ulcerative colitis in high-risk patients

Ulcerative colitis (UC) is a chronic disease involving the large intestine which causes inflammation along with local and systemic symptoms. It affects individuals worldwide, with a higher prevalence in Canada. The course of this disease has long been unpredictable, with remission possible in some patients and frequent recurrence in others.

20 Jan 2010

Telaprevir effective in HCV patients

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that data from recent clinical trials suggest that Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir is efficacious in hepatitis C virus patients who have not responded to previous treatment with peg-IFN/ribavirin. In contrast, the efficacy of Merck's (formerly Schering-Plough) boceprevir in treatment nonresponders has yet to be proven.

20 Jan 2010

Scientists explore new ways to counteract viral infections

For the first time the research world has managed to measure the energy that is used when a virus infects a cell. The aim is to find a way to reduce the amount of energy inside the virus and thereby ultimately find a medicine that can counteract infections.

20 Jan 2010

Boston University School of Public Health explores changing global health system for malaria research

This week PLoS Medicine publishes the third in a four-part series of policy papers examining the ways in which global health institutions and arrangements are changing and evolving.

20 Jan 2010

Antibiotics can reduce infections post-Caesarean section

Having a baby by Caesarean section is becoming increasingly common, despite the higher risks associated with the surgery compared to a vaginal birth. One important concern is the risk of infection, which is between five and 20 times greater for women who undergo scheduled or emergency Caesarean section.

20 Jan 2010

UCI finding could complicate quest to eradicate deadly disease in humans

Chimpanzees were known to carry the parasite Plasmodium reichenowi, but most scientists assumed the two parasites had existed separately in humans and chimpanzees for the last 5 million years.

20 Jan 2010

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe's telaprevir than Merck's boceprevir.

20 Jan 2010

Statins may protect SCD children from pneumococcal infection

New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease.

20 Jan 2010

Dynamic mapping may help in detecting links between diseases and environmental exposures

A team of researchers has developed a dynamic mapping tool to gain a more nuanced view of the links between diseases and environmental exposures. The application of the method is illustrated by a number of examples of associations between environmental exposures and Salmonella infections among people in the US age 65 and over in 2002.

20 Jan 2010

Disease/Infection News

Study: PrEP treatment offers protection against HIV transmission in humanized mice

Discovery of new class of compounds may help fight hepatitis C

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

Study identifies new mechanism that causes allergic response in people

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

Acyclovir does not reduce risk of HIV transmission for people infected with both HIV and HSV-2

Research shows strong links between COPD and heart function

GSK to offer scientists access to compounds, lab space to fight malaria

One-legged cycling can improve overall fitness in COPD patients

Circumcising newborn males cost effective strategy for HIV prevention, Rwandan study finds

Researchers develop more effective way to predict the spread of foot-and-mouth disease

Data may help identify severity of ulcerative colitis in high-risk patients

Telaprevir effective in HCV patients

Scientists explore new ways to counteract viral infections

Boston University School of Public Health explores changing global health system for malaria research

Antibiotics can reduce infections post-Caesarean section

UCI finding could complicate quest to eradicate deadly disease in humans

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Statins may protect SCD children from pneumococcal infection

Dynamic mapping may help in detecting links between diseases and environmental exposures

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News